Αρχική World News ASCO20 Virtual Research Round Up Podcast: Central Nervous System Tumors and Lymphoma

ASCO20 Virtual Research Round Up Podcast: Central Nervous System Tumors and Lymphoma

In the annual Research Round Up podcast series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field presented at the ASCO20 Virtual Scientific Program?” In this final episode of 2020, 2 editors discuss a range of research presented in central nervous system (CNS) tumors and lymphoma.

Listen below, and subscribe to Cancer.Net Podcasts on Apple Podcasts or Google Play to catch up on all the highlighted research from this year’s meeting.

Dr. Glenn Lesser, the 2020 Cancer.Net Associate Editor for Central Nervous System Tumors, discusses new research in cancer that has started in the brain or spinal cord, as well as cancer that has spread to the brain from another part of the body, called secondary or metastatic cancer.  

First, he discusses a study on whether adding low-dose whole-brain radiation therapy to standard chemotherapy helps people with a specific type of non-Hodgkin lymphoma called primary CNS lymphoma  live longer. [4:24] He also discusses a study that looked at whether adding a targeted therapy called tucatinib (Tukysa) to chemotherapy could treat HER2-positive breast cancer that has spread to the brain. [7:47]

Dr. Michael Williams, the 2020 Cancer.Net Associate Editor for Lymphoma, discusses 3 studies across the field of lymphoma. First, he discusses a study that compared the immunotherapy drug pembrolizumab (Keytruda) with a standard treatment for Hodgkin lymphoma that was resistant to the initial treatment, called refractory, or if it came back after treatment, called recurrent or relapsed. [13:58] Next, he discusses a study comparing 2 targeted therapy drugs, ibrutinib (Imbruvica) and zanubrutinib (Brukinsa), for people with a specific type of non-Hodgkin lymphoma known as Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma). [16:32] Finally, he discusses a study that looked at treating people with refractory or recurrent follicular lymphoma with a chimeric antigen receptor (CAR) T-cell therapy called axicabtagene ciloleucel (Yescarta). [19:09]

Disclosure information for this podcast’s speakers can be found in their individual biographies, which are linked to in the paragraphs above.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Cancer.Net podcasts are edited for length and content.

Source

Προηγούμενο άρθροSummer Sun Safety Tips
Επόμενο άρθροFDA Approves Azacitidine Tablets for Acute Myeloid Leukaemia

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Making Important Decisions During Cancer: A Survivor’s Story

Bethany Hart lives with her husband Kevin, sons, and 3 dogs in the suburbs of Indianapolis, Indiana. She is a survivor of small cell neuroendocrine cervical cancer....

Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer

October 26, 2021, by NCI Staff Atezolizumab (Tecentriq) is approved as an additional treatment for some patients with stage II to IIIA (pictured) non-small cell...

Cure Probability Models for Evaluation of Patients with a Previous Cancer Diagnosis for Solid Organ Transplantation

Findings from a first study that applied a formal statistical framework to inform the evaluation of transplant candidates with a previous cancer diagnosis were...

Teacher Reads To Students One Day After Having Brain Surgery

Meucci - who had her surgery on a Wednesday - was going live from her intensive care unit hospital room that very next Thursday...

6 things you need to know about cervical screening

This article was originally published in 2017 during Cervical Screening Awareness Week. It has now been reviewed and updated. Cervical screening, also known as the...

EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan

On 14 October 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...